Pharmacokinetics and Pharmacodynamics of Lurasidone Hydrochloride, a Second-Generation Antipsychotic: A Systematic Review of the Published Literature

Clinical Pharmacokinetics

Volumn 56, Issue 5, 2017, Pages 493-503

  Greenberg, William M ^a,b   Citrome, Leslie ^c  

^a St George's University School of Veterinary Medicine True Blue   (Grenada)

^b Mental Health Association of Rockland County   (United States)

^c NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2A ADRENERGIC RECEPTOR; ALPHA 2C ADRENERGIC RECEPTOR; CYANOCOBALAMIN; CYTOCHROME P450 3A4; DOPAMINE 2 RECEPTOR; INTRINSIC FACTOR; LURASIDONE; SEROTONIN 1A RECEPTOR; SEROTONIN 2A RECEPTOR; SEROTONIN 7 RECEPTOR; CYP3A4 PROTEIN, HUMAN; CYTOCHROME P450 3A; NEUROLEPTIC AGENT; SEROTONIN 2 ANTAGONIST;

ADULT; AGE; ANTICHOLINERGIC EFFECT; AREA UNDER THE CURVE; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG METABOLISM; HUMAN; KIDNEY FAILURE; LIVER FAILURE; MAXIMUM PLASMA CONCENTRATION; PARTIAL AGONISM; PHARMACODYNAMICS; PHARMACOKINETICS; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; VOLUME OF DISTRIBUTION; ANIMAL; BLOOD; DRUG EFFECTS; KIDNEY; METABOLISM; SCHIZOPHRENIA;

AGE FACTORS; ANIMALS; ANTIPSYCHOTIC AGENTS; CYTOCHROME P-450 CYP3A; HUMANS; KIDNEY; LURASIDONE HYDROCHLORIDE; SCHIZOPHRENIA; SEROTONIN 5-HT2 RECEPTOR ANTAGONISTS;

EID: 84990990600     PISSN: 03125963     EISSN: 11791926     Source Type: Journal    
DOI: 10.1007/s40262-016-0465-5     Document Type: Review

References (81)

1. Volavka J, Citrome L. Oral antipsychotics for the treatment of schizophrenia: heterogeneity in efficacy and tolerability should drive decision-making. Expert Opin Pharmacother. 2009;10:1917–28.
2. Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet. 2013;382(9896):951–62.
3. Citrome L, Eramo A, Francois C, Duffy R, Legacy SN, Offord SJ, et al. Lack of tolerable treatment options for patients with schizophrenia. Neuropsychiatr Dis Treat. 2015;11:3095–104.
4. Citrome L, Johnston S, Nadkarni A, Sheehan JJ, Kamat SA, Kalsekar I. Prevalence of pre-existing risk factors for adverse events associated with atypical antipsychotics among commercially insured and Medicaid insured patients newly initiating atypical antipsychotics. Curr Drug Saf. 2014;9:227–35.
5. Food and Drug Administration. Drug approval package. Latuda (lurasidone hydrochloride) tablets. Sunovion Pharmaceuticals, Inc. clinical review; pharmacology review(s); clinical pharmacology biopharmaceutics review(s). http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/200603Orig1s000PharmR.pdf. Accessed 12 Jun 2016.
6. Highlights of prescribing information: Latuda. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/200603s015lbl.pdf. Accessed 3 Apr 2016.
7. European Medicines Agency. Latuda. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002713/human_med_001737.jsp&mid=WC0b01ac058001d124. Accessed 3 Apr 2016.
8. Summary Basis of Decision (SBD) for Latuda. Health Canada. 2012. http://www.hc-sc.gc.ca/dhp-mps/prodpharma/sbd-smd/drug-med/sbd_smd_2012_latuda_145406-eng.php#a2. Accessed 3 Apr 2016.
9. Zohar J, Nutt DJ, Kupfer DJ, Moller HJ, Yamawaki S, Spedding M, et al. A proposal for an updated neuropsychopharmacological nomenclature. Eur Neuropsychopharmacol. 2014;24:1005–14.
10. Meltzer HY, Li Z, Kaneda Y, Ichikawa J. Serotoninreceptors: theirkeyrole in drugs to treatschizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27:1159–72.
11. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet. 2009;373:31–41.
12. Preskorn S, Ereshefsky L, Chiu YY, Poola N, Loebel A. Effect of food on the pharmacokinetics of lurasidone: results of two randomized, open-label, crossover studies. Hum Psychopharmacol Clin Exp. 2013;28:495–505.
13. Citrome L. Lurasidone for schizophrenia: a brief review of a new second-generation antipsychotic. Clin Schizophr Relat Psychoses. 2011;4:251–7.
14. Meyer JM, Loebel AD, Schweizer E. Lurasidone: a new drug in development for schizophrenia. Expert Opin Investig Drugs. 2009;18:1715–26.
15. Lee KR, Chae YJ, Koo TS. Pharmacokinetics of lurasidone, a novel atypical anti-psychotic drug, in rats. Xenobiotica. 2011;41:1100–7.
16. 2 receptor occupancy by lurasidone using positron emission tomography in healthy male subjects. Psychopharmacology. 2013;229(2):245–52.
17. Nordström AL, Farde L, Wiesel FA, Forslund K, Pauli S, Halldin C, et al. Central D2-dopamine receptor occupancy in relation to antipsychotic drug effects: a double-blind PET study of schizophrenic patients. Biol Psychiatry. 1993;33:227–35.
18. Uchida H, Takeuchi H, Graff-Guerrero A, Suzuki T, Watanabe K, Mamo DC. Dopamine D2 receptor occupancy and clinical effects: a systematic review and pooled analysis. J Clin Psychopharmacol. 2011;31:497–502.
19. Kapur S, Zipursky RB, Remington G. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry. 1999;156:286–93.
20. 2 receptor occupancy from plasma levels of antipsychotic drugs: a systematic review and pooled analysis. J Clin Psychopharmacol. 2011;31:318–25.
21. 2 receptor occupancy following lurasidone treatment in patients with schizophrenia or schizoaffective disorder. CNS Spectr. 2014;19:176–81.
22. Chiu YY, Ereshefsky L, Preskorn SH, Poola N, Loebel A. Lurasidone drug-drug interaction studies: a comprehensive review. Drug Metab Drug Interact. 2014;29:191–202.
23. Findling RL, Goldman R, Chiu YY, Silva R, Jin F, Pikalov A, et al. Pharmacokinetics and tolerability of lurasidone in children and adolescents with psychiatric disorders. ClinTher. 2015;37(12):2788–97.
24. Weisler RH. Carbamazepine extended-release capsules: a new treatment option for bipolar I disorder. Expert Rev Neurother. 2005;5:587–95.
25. Ketter TA, Wang PW, Miller S. Bipolar therapeutics update 2014: a tale of 3 treatments. J Clin Psychiatry. 2015;76:69–70.
26. 1A receptor activity. J Pharmacol Exp Ther. 2010;334A:171–81.
27. Caccia S, Pasina L, Nobili A. Critical appraisal of lurasidone in the management of schizophrenia. Neuropsychiatr Dis Treat. 2012;8:155–68.
28. Fountoulakis KN, Gazouli M, Kelsoe J, Akisal H. The pharmacological properties of lurasidone and their role in its antidepressant efficacy in bipolar disorder. Eur Neuropsychopharmacol. 2015;25:335–42.
29. European Medicines Agency. Assessment report—Latuda. Procedure no. EMEA/H/C/002713/0000. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002713/WC500164684.pdf. Accessed 15 Jun 2016.
30. ICH Harmonized Tripartite Guideline. The clinical evaluation of QT/QTC interval prolongation and proarrhythymic potential for non-antiarrhythmic drugs. E14. Current Step 4 version dated 12 May 2005. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E14/E14_Guideline.pdf Accessed 15 Jun 2016.
31. Meltzer HY. The role of serotonin in antipsychotic drug action. Neuropsychopharmacol. 1999;21:106S–15S.
32. 2A receptors stimulate ACTH, corticosterone, oxytocin, renin, and prolactin release and activate hypothalamic CRF and oxytocin-expressing cells. J Neurosci. 2001;21:3572–9.
33. Goldberg TE, Ragland JD, Torrey EF, Gold JM, Bigelow LB, Weinberger DR. Neuropsychological assessment of monozygotic twins discordant for schizophrenia. Arch Gen Psychiatry. 1990;47:1066–72.
34. Goldberg TE, Gold JM. Neurocognitive functioning in patients with schizophrenia: an overview. In: Bloom FE, Kupfer DJ, editors. Psychopharmacology: the fourth generation of progress. New York: Raven; 1995. p. 1245–57.
35. Green MD. What are the functional consequences of neurocognitive deficits in schizophrenia? Am J Psychiatry. 1996;153:321–30.
36. Schizophrenia. In: American Psychiatric Association (ed). Diagnostic and statistical manual of mental disorders. Fifth ed. Arlington: American Psychiatric Association, 2013. pp. 99–105.
37. Marder SR. The NIMH-MATRICS project for developing cognition-enhancing agents for schizophrenia. Dialog Clin Neurosci. 2006;8:109–13.
38. Keefe RS, Harvey PD. Cognitive impairment in schizophrenia. Handb Exp Pharmacol. 2012;213:11–37.
39. Bilder RM, Goldman RS, Volavka J, Czobor P, Hoptman M, Sheitman B, et al. Neurocognitive effects of clozapine, olanzapine, risperidone, and haloperidol in patients with chronic schizophrenia or schizoaffective disorder. Am J Psychiatry. 2002;159:1018–28.
40. Harvey PD, Green MF, McGurk SR, Meltzer HY. Changes in cognitive functioning with risperidone and olanzapine treatment: a large-scale, double-blind, randomized study. Psychopharmacology. 2003;169:404–11.
41. Davidson M, Galderisi S, Weiser M, Werbeloff N, Fleischhacker WW, Keefe RS, et al. Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST). Am J Psychiatry. 2009;166:675–82.
42. Harvey PD, Meltzer H, Simpson GM, Potkin SG, Loebel A, Siu C, et al. Improvement in cognitive function following a switch to ziprasidone from conventional antipsychotics, olanzapine, or risperidone in outpatients with schizophrenia. Schizophr Res. 2004;66:101–13.
43. Keefe RS, Silva S, Perkins DO, Lieberman JA. The effects of atypical antipsychotic drugs on neurocognitive impairment in schizophrenia: a review and meta-analysis. Schizophr Bull. 1999;25:201–22.
44. Enomoto T, Ishibashi T, Tokuda K. IshiyamaT, Toma S, Ito A. Lurasidone reverses MK-801-induced impairment of learning and memory in the Morris water maze and radial-arm maze test in rats. Behav Brain Res. 2008;186:197–207.
45. Gasbarri A, Cifariello A, Pompili A, Meneses A. Effect of 5-HT7 antagonist SB-269970 in the modulation of working and reference memory in the rat. Behav Brain Res. 2008;195:164–70.
46. Ishiyama T, Tokuda K, Ishibashi T, Ito A, Toma S, Ohno Y. Lurasidone (SM-13496, a novel atypical antipsychotic drug, reverses MK-801-induced impairment of learning and memory in the rat passive-avoidance test. Eur J Pharmacol. 2007;572:160–70.)
47. Roberts AJ, Krucker T, Levy CL, Slanina KA, Sutcliffe JG, Hedlund PB. Mice lacking 5-HT receptors show specific impairments in contextual learning. Eur J Neurosci. 2004;19:1913–22.
48. 7receptorisinvolved in allocentricspatialmemory information processing. Behav Brain Res. 2009;202:26–31.
49. 7 receptor stimulation and blockade: a therapeutic paradox about memory formation and amnesia. Front BehavNeurosci. 2014;8:207.
50. 7 receptor inhibition and inactivation induce antidepressant like behavior and sleep pattern. Biol Psychiatry. 2005;58:831–7.
51. 7 receptor antagonist SB 269970 in animal models of anxiety and depression. Neuropharmacology. 2006;51:578–86.
52. Bieńkowski P, Dudek D, Samochowiec J. Towards better non-selectivity: the role of 5-HT7 receptors in therapeutic efficacy of a second-generation antipsychotic—lurasidone. Psychiatr Pol. 2015;49:243–53.
53. Perrone-Capano C, Adriani W. Editorial: further understanding of serotonin 7 receptors’ neuro-psycho-pharmacology. Front Behav Neurosci. 2015;9:307.
54. 2A receptors in depression. J Psychiatry Neurosci. 2004;29:252–65.
55. Bristol-Myers Squibb Company. Highlights of prescribing information: BuSpar. http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/018731s051lbl.pdf. Accessed 24 Jun 2016.
56. Hellerstein DJ, Flaxer J. Vilazodone for the treatment of major depressive disorder: an evidence-based review of its place in therapy. Core Evid. 2015;10:49–62.
57. Odagaki Y, Totoshima R, Yamauchi T. Trazodone and its active metabolite m-chlorophenylpiperazine as partial agonists at 5-HT1A receptors assessed by [35S]GTPgammaS binding. J Psychopharmacol. 2005;19:235–41.
58. Schwartz TL, Siddiqui UA, Stahl SM. Vilazodone: a brief pharmacological and clinical review of the novel serotonin partial agonist and reuptake inhibitor. Ther Adv Psychopharmacol. 2011;1:81–7.
59. Trivedi MH, Fava M, Wisniewski SR, Thase ME, Quitkin F, Warden D, et al. Medication augmentation after the failure of SSRIs for depression. N Engl J Med. 2006;354:1243–52.
60. Schatzberg AF, Blier P, Culpepper L, Jain R, Papakostas GI, Thase ME. An overview of vortioxetine. J Clin Psychiatry. 2014;75:1411–8.
61. FDA Center for Drug Evaluation and Research. Summary minutes meeting of the Psychopharmacologic Drugs Advisory Committee, December 1, 2015. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/PsychopharmacologicDrugsAdvisoryCommittee/UCM481253.pdf. Accessed 28 Jun 2016.
62. 7 and its interaction in emotional learning and memory. Front Pharmacol. 2015;6:162.
63. Weinberger DR, Berman KF, Zec RF. Physiologic dysfunction of dorsolateral prefrontal cortex in schizophrenia: I. Regional cerebral blood flow evidence. Arch Gen Psychiatry. 1986;43:114–24.
64. Yuen EY, Li X, Wei J, Horiguchi M, Meltzer HY, Yan Z. The novel antipsychotic drug lurasidone enhances N-methyl-D-aspartate receptor-mediated synaptic responses. Mol Pharmacol. 2012;81:113–9.
65. Murai T, Nakako T, Ikeda K, Ikejiri M, Ishiyama T, Taiji M. Lack of dopamine D4 receptor affinity contributes to the precognitive effect of lurasidone. Brain Res. 2014;261:26–30.
66. Brosda J, Jantschak F, Pertz HH. α2-adrenoreceptors are targets for antipsychotic drugs. Psychopharmacology (Berlin). 2014;231:801–12.
67. Jantschak F, Brosda J, Franke RT, Fink H, Möller D, Hübner H, et al. Pharmacological profile of 2-bromoterguride at human dopamine D2, porcine serotonin 5-hyrdroxytryptamine 2A, and α2C-adrenergic receptors, and its antipsychotic-like effects in rats. J Pharmacol Exp Ther. 2013;347:57–68.
68. Sallinen J, Holappa J, Koivisto A, Kuokkanen K, Chapman H, Lehtimäki J, et al. Basic. Clin Pharmacol Toxicol. 2013;113:239–49.
69. Marcus MM, Wiker C, Frånberg O, Konradsson-Geuken A, Langlois X, Jardemark K, et al. Adjunctive alpha2-adrenoreceptor blockadeenhances the antipsychotic-likeeffect of risperidone and facilitatescorticaldopaminergic and glutamatergic, NMDA receptor-mediatedtransmission. Int J Neuropsychopharmacol. 2010;13:891–903.
70. Imaki J, Mae Y, Shimizu S. OhnoY. Therapeutic potential of alpha2 adrenoceptor antagonism for antipsychotic-induced extrapyramidal motor disorders. Neurosci Lett. 2009;454:143–7.
71. Citrome L. Lurasidone for the acute treatment of adults with schizophrenia: what is the number needed to treat, number needed to harm, and likelihood to be helped or harmed? Clin Schizophr Relat Psychoses. 2012;6:76–85.
72. Citrome L, Ketter TA, Cucchiaro J, Loebel A. Clinical assessment of lurasidone benefit and risk in the treatment of bipolar I depression using number needed to treat, number needed to harm, and the likelihood to be helped or harmed. J Affect Disord. 2014;155:20–7.
73. 2Creceptor and antipsychotic-inducedweight gain: mechanisms and genetics. J Psychopharmacol. 2006;20:15–8.
74. Citrome L. Lurasidone in schizophrenia: new information about dosage and place in therapy. Adv Ther. 2012;29:815–25.
75. Abbas AI, Hedlund PB, Huang XP, Tran TB, Meltzer HY, Roth BL. Amisulpride is a potent 5-HT7 antagonist: relevance for antidepressant actions in vivo. Psychopharmacol (Berl). 2009;205:119–28.
76. 7 receptor by risperidone, 9-OH-risperidone, and other inactivating antagonists. Mol Pharmacol. 2009;75:374–80.
77. Stahl S. Modes and nodes explain the mechanism of action of vortioxetine, a multimodal agent (MMA): enhancing serotonin release by combining serotonin (5HT) transporter inhibition with actions at 5HT receptors (5HT1A, 5HT1B, 5HT1D, 5HT7 receptors). CNS Spectr. 2015;20:93–7.
78. Highlights of prescribing information: Seroquel XR. http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/022047s038lbl.pdf. Accessed 30 Jun 2016.
79. Highlights of prescribing information: Invega. http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021999s030lbl.pdf. Accessed 30 Jun 2016.
80. Highlights of prescribing information: Viibryd. http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/022567s013lbl.pdf. Accessed 28 Jun 2016.
81. Madan JR, Pawar KT, Dua K. Solubility enhancement studies on lurasidone hydrochloride using mixed hydrotropy. Int J Pharm Investig. 2015;5:114–20.